Programs

Three pillars on one HSC engineering foundation.

Banked donor products for diseases that need cells now, an autologous path for diseases that need tolerance, and a manufacturing concept that could bring both to the bedside.

01 Off-the-shelf · Allogeneic

Banked engineered donor HSPCs

Healthy-donor cells engineered to stay invisible to recipient immunity for as long as each disease requires — banked, cryopreserved, and infused without HLA matching or donor-search delay.

All three indications preclinical
Radiation injury Lead · UHRP-Bridge
SCD & β-thalassemia Hemoglobinopathies
SCID & selected IEIs Immune deficiencies
Explore pillar 01 →
02 Autologous · Tolerance

Autologous HSC engineering

A patient's own HSCs engineered to teach their immune system what to tolerate — donor-specific tolerance in transplantation, and regulation directed only at inflamed tissue in autoimmune disease.

Platform direction · Not an active clinical program
Transplant tolerance Longer-term
Autoimmune disease Exploratory · IBD, MS
Explore pillar 02 →
03 ECEP · Bedside engineering

Closed-loop extracorporeal platform

A closed, automated engineering concept designed to bring controlled cell engineering to the point of care — reducing manufacturing complexity and supporting scalable workflows.

Enabling technology · In development
Time to treat months → 12–24 h
Cost per patient $2–3M → ~$200K
Targets, not results. Not required for the lead program's first IND-enabling path.
Explore pillar 03 →

See how the three pillars sequence.

The pipeline page sets out stage, near-term milestones and the market model for each.

View the pipeline